Engineered Bacteria Delivers Cancer Drug Directly to Tumors

Researchers are exploring a novel approach to cancer treatment, harnessing the power of genetically modified bacteria to seek out and destroy tumors. A team led by Tianyu Jiang at Shandong University in China has successfully engineered Escherichia coli Nissle 1917 (EcN), a probiotic bacterium, to produce and deliver an anti-cancer drug directly to tumor sites in mice. This innovative strategy, detailed in a recent publication in PLOS Biology, represents a significant step towards more targeted and effective cancer therapies.

Engineering Bacteria for Targeted Drug Delivery

The core of this research lies in the genetic modification of EcN, a probiotic strain naturally found in the human gut. Researchers reprogrammed the bacteria to synthesize Romidepsin (FK228), an FDA-approved drug used in the treatment of certain cancers. This transforms the bacteria into what researchers describe as a “living therapy” – a microscopic drug factory capable of navigating the body and delivering its payload directly to cancerous cells. The study, as reported by Wutshot, demonstrated that the modified EcN bacteria successfully infiltrated breast cancer tumors in a mouse model.

How Does it Work?

The approach leverages the natural tendency of EcN to colonize tumors. By engineering the bacteria to produce Romidepsin within the tumor microenvironment, the drug is concentrated precisely where it’s needed, potentially maximizing its therapeutic effect although minimizing systemic side effects. This “dual-action” therapy, as described in the Jurnalul report, combines the tumor-colonizing ability of the bacteria with the anti-cancer properties of the drug. Traditional chemotherapy often affects both cancerous and healthy cells, leading to a range of debilitating side effects. This targeted delivery system aims to circumvent that issue.

The Promise of Targeted Cancer Therapies

Targeted therapies are a major focus of modern cancer research. The idea is to develop treatments that specifically attack cancer cells while sparing healthy tissue. Using bacteria as vehicles for drug delivery is a relatively new, but promising, avenue within this field. The research builds on the understanding that the microbiome – the community of microorganisms living in and on our bodies – plays a crucial role in health and disease. Scientists are increasingly exploring ways to manipulate the microbiome to improve health outcomes, including cancer treatment.

Study Details and Limitations

The study involved introducing breast cancer tumor cells into mice and then treating them with the modified EcN bacteria. The bacteria were able to accumulate within the tumors and release Romidepsin both in laboratory settings and within the animals. However, it’s crucial to note that this research is still in its early stages. The findings are based on experiments conducted in mice and further research is needed to determine whether this approach will be safe and effective in humans. As highlighted in the Shandong University State Key Laboratory of Microbial Technology website, Tianyu Jiang’s research group is actively involved in exploring tumor-targeting bacteria-based therapies, with ongoing projects focused on improving drug delivery and efficacy.

What Comes Next: From Lab to Clinic

Before this therapy can be tested in humans, several critical questions need to be addressed. Researchers must thoroughly evaluate the safety of using genetically modified bacteria in the body, assess potential side effects, and develop methods for safely removing the bacteria after treatment is complete. The study authors acknowledge the need for further investigation into these areas. Future studies will likely focus on optimizing the bacterial strain, improving drug delivery efficiency, and exploring the potential of this approach in different types of cancer.

Public Health Implications and Ongoing Research

The development of targeted cancer therapies has the potential to significantly improve patient outcomes and reduce the burden of cancer worldwide. While this specific approach is still in its early stages, it represents a promising new direction in cancer research. The broader field of microbiome-based therapies is rapidly evolving, with ongoing research exploring the potential of using bacteria to treat a wide range of diseases. The National Cancer Institute (NCI) supports numerous research projects focused on understanding the role of the microbiome in cancer development and treatment. (National Cancer Institute)

Tianyu Jiang’s team at Shandong University continues to investigate this area, with ongoing projects supported by initiatives like the Future Plan for Young Scholars of Shandong University, as noted on the university’s website. The success of this research will ultimately depend on the results of clinical trials in humans, which will determine whether this innovative approach can translate into a safe and effective cancer treatment for patients.